Table 1.
Demography and baseline characteristics of evaluable patients in study A (patients naive to tofacitinib) and study B (patients using tofacitinib)
| Study A | Study B | |||
|---|---|---|---|---|
| Tofacitinib 10 mg twice daily | ||||
| Tofacitinib 10 mg twice daily (N=102) |
Placebo (N=98) |
Continuous (N=92) |
Withdrawn (N=91) |
|
| Female, n (%) | 75 (73.5) | 79 (80.6) | 78 (84.8) | 79 (86.8) |
| Age in years, median (range) | 53 (25–82) | 53 (23–77) | 57.0 (28–78) | 54.0 (24–72) |
| DAS28-4 (ESR), mean (SD) | 6.03 (1.05) | 5.78 (1.10) | 3.64 (1.36) | 3.71 (1.34) |
| Background MTX, n (%) | 57 (55.9) | 55 (56.1) | 55 (59.8) | 55 (60.4) |
| Prednisone use, n (%) | 38 (37.3) | 31 (31.6) | 39 (42.4) | 46 (50.5) |
| Evidence of influenza seroprotection,* n (%) | 20 (19.6) | 32 (32.7) | 22 (23.9) | 23 (25.3) |
*Protection status (1:40 in two or more of three antigens) to influenza vaccine at 35-days after vaccination.
DAS, disease activity score; ESR, erythrocyte sedimentation rate; MTX, methotrexate.